Compare $BIAF vs $PMCB | Chartloom

Compare

$BIAF vs $PMCB

bioAffinity Technologies Inc · PharmaCyte Biotech Inc

BIAF

bioAffinity Technologies Inc

PMCB

PharmaCyte Biotech Inc

Compare $BIAF vs $PMCB

Comparing bioAffinity Technologies Inc and PharmaCyte Biotech Inc

BIAFbioAffinity Technologies Inc

PMCBPharmaCyte Biotech Inc

BIAFbioAffinity Technologies Inc

Market cap

$37M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-23.2%

YTD performance

-74.2%

52W performance

-89.7%

FCF yield

-31.5%

PMCBPharmaCyte Biotech Inc

Market cap

$4M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-45.2%

52W performance

-60.4%

FCF yield

-90.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BIAF

PMCB

Detailed metrics comparison

BIAF

bioAffinity Technologies Inc

PMCB

PharmaCyte Biotech Inc

Market Cap

BIAF$37M

PMCB$4M

Enterprise Value

BIAF$35M

PMCB$-13M

Price

BIAF$4.73

PMCB$0.40

P/E Ratio

BIAFN/A

PMCBN/A

P/S Ratio

BIAF6.23x

PMCB107.65x

EV/Sales

BIAF5.93x

PMCB-336.93x

EV/EBITDA

BIAF0.00x

PMCB0.00x

P/B Ratio

BIAF1.87x

PMCB0.14x

P/FCF Ratio

BIAFN/A

PMCBN/A

EV/FCF

BIAF-3.02x

PMCB3.40x

PEG Ratio

BIAFN/A

PMCBN/A

Forward P/E (NTM)

BIAFN/A

PMCBN/A

Forward P/S (NTM)

BIAFN/A

PMCBN/A

Revenue (TTM)

BIAF$6M

PMCB$0

Revenue Growth (YoY)

BIAF-23.2%

PMCBN/A

Forward Rev Growth

BIAF0.0%

PMCB0.0%

Gross Margin (TTM)

BIAF34.6%

PMCB81.7%

Operating Margin (TTM)

BIAF0.0%

PMCB0.0%

EBITDA Margin (TTM)

BIAF-202.8%

PMCB0.0%

Net Margin (TTM)

BIAF-257.3%

PMCB0.0%

FCF Margin (TTM)

BIAF-196.0%

PMCBN/A

Net Income (TTM)

BIAF$-15M

PMCB$-21M

FCF (TTM)

BIAF$-12M

PMCB$-4M

EPS (TTM)

BIAF-$43.57

PMCB-$1.92

ROE (TTM)

BIAF-25727.0%

PMCB-4588.0%

ROA (TTM)

BIAF-15954.0%

PMCB-3307.0%

ROIC (TTM)

BIAF-23305.0%

PMCB-4588.0%

Cash

BIAF$2M

PMCB$18M

Debt

BIAF$634K

PMCB$0

Net Cash/Debt

BIAF$2M

PMCB$18M

Current Ratio (TTM)

BIAF1.44x

PMCB40.30x

Quick Ratio (TTM)

BIAF1.36x

PMCB40.25x

Debt/Equity (TTM)

BIAF0.17x

PMCB0.00x

Debt/Assets (TTM)

BIAF0.0%

PMCB0.0%

Interest Coverage (TTM)

BIAFN/A

PMCBN/A

Net Debt/EBITDA (TTM)

BIAF0.00x

PMCB0.00x

Beta

BIAF-1.26

PMCB0.74

52W Performance

BIAF-89.7%

PMCB-60.4%

YTD Performance

BIAF-74.2%

PMCB-45.2%

% from 52W High

BIAF-94.1%

PMCB-73.2%

% from 52W Low

BIAF3.6%

PMCB21.1%

Asset Turnover (TTM)

BIAF0.62x

PMCB0.02x

FCF Yield (TTM)

BIAF-31.5%

PMCB-90.7%

Earnings Yield (TTM)

BIAF-41.3%

PMCB-475.0%

Dividend Yield (TTM)

BIAFN/A

PMCBN/A

Rule of 40

BIAF-219.2

PMCB0.0

EV/GP/RG

BIAFN/A

PMCBN/A

Ticker research

View BIAF research View PMCB research

Metric	BIAF bioAffinity Technologies Inc	PMCB PharmaCyte Biotech Inc
Market & Valuation
Market Cap	$37M	$4M
Enterprise Value	$35M	$-13M
Price	$4.73	$0.40
P/E Ratio	N/A	N/A
P/S Ratio	6.23x	107.65x
EV/Sales	5.93x	-336.93x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.87x	0.14x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.02x	3.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	-23.2%	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	34.6%	81.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-202.8%	0.0%
Net Margin (TTM)	-257.3%	0.0%
FCF Margin (TTM)	-196.0%	N/A
Net Income (TTM)	$-15M	$-21M
FCF (TTM)	$-12M	$-4M
EPS (TTM)	-$43.57	-$1.92
ROE (TTM)	-25727.0%	-4588.0%
ROA (TTM)	-15954.0%	-3307.0%
ROIC (TTM)	-23305.0%	-4588.0%
Financial Health
Cash	$2M	$18M
Debt	$634K	$0
Net Cash/Debt	$2M	$18M
Current Ratio (TTM)	1.44x	40.30x
Quick Ratio (TTM)	1.36x	40.25x
Debt/Equity (TTM)	0.17x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.26	0.74
52W Performance	-89.7%	-60.4%
YTD Performance	-74.2%	-45.2%
% from 52W High	-94.1%	-73.2%
% from 52W Low	3.6%	21.1%
Efficiency & Yields
Asset Turnover (TTM)	0.62x	0.02x
FCF Yield (TTM)	-31.5%	-90.7%
Earnings Yield (TTM)	-41.3%	-475.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-219.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BIAF research	View PMCB research

Valuation

P/S Ratio

BIAF

6.23x

PMCB

107.65x

EV/FCF

BIAF

-3.02x

PMCB

3.40x

Growth & revenue

Revenue Growth TTM

BIAF

-23.2%

Forward Revenue Growth

BIAF

0.0%

PMCB

0.0%

Profitability & performance

Gross Margin

PMCB

81.7%

BIAF

34.6%

ROE

PMCB

-4588.0%

BIAF

-25727.0%

FCF Yield %

BIAF

-31.5%

PMCB

-90.7%

52-Week Performance

PMCB

-60.4%

BIAF

-89.7%

Detailed metrics comparison

BIAF

bioAffinity Technologies Inc

PMCB

PharmaCyte Biotech Inc

Market Cap

BIAF$37M

PMCB$4M

Enterprise Value

BIAF$35M

PMCB$-13M

Price

BIAF$4.73

PMCB$0.40

P/E Ratio

BIAFN/A

PMCBN/A

P/S Ratio

BIAF6.23x

PMCB107.65x

EV/Sales

BIAF5.93x

PMCB-336.93x

EV/EBITDA

BIAF0.00x

PMCB0.00x

P/B Ratio

BIAF1.87x

PMCB0.14x

P/FCF Ratio

BIAFN/A

PMCBN/A

EV/FCF

BIAF-3.02x

PMCB3.40x

PEG Ratio

BIAFN/A

PMCBN/A

Forward P/E (NTM)

BIAFN/A

PMCBN/A

Forward P/S (NTM)

BIAFN/A

PMCBN/A

Revenue (TTM)

BIAF$6M

PMCB$0

Revenue Growth (YoY)

BIAF-23.2%

PMCBN/A

Forward Rev Growth

BIAF0.0%

PMCB0.0%

Gross Margin (TTM)

BIAF34.6%

PMCB81.7%

Operating Margin (TTM)

BIAF0.0%

PMCB0.0%

EBITDA Margin (TTM)

BIAF-202.8%

PMCB0.0%

Net Margin (TTM)

BIAF-257.3%

PMCB0.0%

FCF Margin (TTM)

BIAF-196.0%

PMCBN/A

Net Income (TTM)

BIAF$-15M

PMCB$-21M

FCF (TTM)

BIAF$-12M

PMCB$-4M

EPS (TTM)

BIAF-$43.57

PMCB-$1.92

ROE (TTM)

BIAF-25727.0%

PMCB-4588.0%

ROA (TTM)

BIAF-15954.0%

PMCB-3307.0%

ROIC (TTM)

BIAF-23305.0%

PMCB-4588.0%

Cash

BIAF$2M

PMCB$18M

Debt

BIAF$634K

PMCB$0

Net Cash/Debt

BIAF$2M

PMCB$18M

Current Ratio (TTM)

BIAF1.44x

PMCB40.30x

Quick Ratio (TTM)

BIAF1.36x

PMCB40.25x

Debt/Equity (TTM)

BIAF0.17x

PMCB0.00x

Debt/Assets (TTM)

BIAF0.0%

PMCB0.0%

Interest Coverage (TTM)

BIAFN/A

PMCBN/A

Net Debt/EBITDA (TTM)

BIAF0.00x

PMCB0.00x

Beta

BIAF-1.26

PMCB0.74

52W Performance

BIAF-89.7%

PMCB-60.4%

YTD Performance

BIAF-74.2%

PMCB-45.2%

% from 52W High

BIAF-94.1%

PMCB-73.2%

% from 52W Low

BIAF3.6%

PMCB21.1%

Asset Turnover (TTM)

BIAF0.62x

PMCB0.02x

FCF Yield (TTM)

BIAF-31.5%

PMCB-90.7%

Earnings Yield (TTM)

BIAF-41.3%

PMCB-475.0%

Dividend Yield (TTM)

BIAFN/A

PMCBN/A

Rule of 40

BIAF-219.2

PMCB0.0

EV/GP/RG

BIAFN/A

PMCBN/A

Ticker research

View BIAF research View PMCB research

Metric	BIAF bioAffinity Technologies Inc	PMCB PharmaCyte Biotech Inc
Market & Valuation
Market Cap	$37M	$4M
Enterprise Value	$35M	$-13M
Price	$4.73	$0.40
P/E Ratio	N/A	N/A
P/S Ratio	6.23x	107.65x
EV/Sales	5.93x	-336.93x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.87x	0.14x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.02x	3.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	-23.2%	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	34.6%	81.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-202.8%	0.0%
Net Margin (TTM)	-257.3%	0.0%
FCF Margin (TTM)	-196.0%	N/A
Net Income (TTM)	$-15M	$-21M
FCF (TTM)	$-12M	$-4M
EPS (TTM)	-$43.57	-$1.92
ROE (TTM)	-25727.0%	-4588.0%
ROA (TTM)	-15954.0%	-3307.0%
ROIC (TTM)	-23305.0%	-4588.0%
Financial Health
Cash	$2M	$18M
Debt	$634K	$0
Net Cash/Debt	$2M	$18M
Current Ratio (TTM)	1.44x	40.30x
Quick Ratio (TTM)	1.36x	40.25x
Debt/Equity (TTM)	0.17x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.26	0.74
52W Performance	-89.7%	-60.4%
YTD Performance	-74.2%	-45.2%
% from 52W High	-94.1%	-73.2%
% from 52W Low	3.6%	21.1%
Efficiency & Yields
Asset Turnover (TTM)	0.62x	0.02x
FCF Yield (TTM)	-31.5%	-90.7%
Earnings Yield (TTM)	-41.3%	-475.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-219.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BIAF research	View PMCB research